William Grossman - 16 Jun 2026 Form 4 Insider Report for enGene Therapeutics Inc. (ENGN)

Reporting relationship: Interim Chief Medical Officer, Director
Issuer ticker: ENGN
Reported as of: 16 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jun 2026, 17:40:43 UTC
Prior SEC filing: 23 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Lee Giguere, as attorney-in-fact for the Reporting Person

Key filing fact

William Grossman filed Form 4 for enGene Therapeutics Inc. (ENGN) on 17 Jun 2026.

Key facts

This page summarizes William Grossman's Form 4 filing for enGene Therapeutics Inc. (ENGN).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 17 Jun 2026, 17:40.

Change

Previous filing in this sequence was filed on 23 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001730229 Primary reporting owner

Grossman William

Relationship: Interim Chief Medical Officer, Director
Address: C/O 4868 RUE LEVY, SUITE 220, SAINT-LAURENT, QUEBEC, CANADA
Signature: /s/ Lee Giguere, as attorney-in-fact for the Reporting Person
Signature date: 17 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ENGN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +31,000
Change %
Price: $0.000000^*
Shares after: 31,000
Date: 16 Jun 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 31,000
Exercise price: $1.75
Footnotes: F1

ENGN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +200,000
Change %
Price: $0.000000^*
Shares after: 200,000
Date: 16 Jun 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 200,000
Exercise price: $1.75
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders. These options were granted to the reporting person on June 16, 2026 for his service as a non-executive director, consistent with annual grants made to other non-executive directors of the board.

Footnote F2

This option vests monthly in substantially equal amounts on the 12th day of each month for 12 consecutive months, subject to the reporting person's continued service as Interim Chief Medical Officer at the time of each vesting. These options were granted to the reporting person in connection with his appointment as the Interim Chief Medical Officer of the Company.